Market Cap 8.85M
Revenue (ttm) 1.50M
Net Income (ttm) -12.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -864.00%
Debt to Equity Ratio 0.00
Volume 432,700
Avg Vol 74,278
Day's Range N/A - N/A
Shares Out 5.83M
Stochastic %K 9%
Beta 1.30
Analysts Strong Sell
Price Target $13.67

Company Profile

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid...

Industry: Biotechnology
Sector: Healthcare
Phone: (215) 948-4119
Website: aprea.com
Address:
3805 Old Easton Road, Doylestown, United States
Bulltrader988
Bulltrader988 Oct. 25 at 8:17 PM
$APRE 👃👀 https://finviz.com/quote.ashx?t=APRE&ty=c&ta=1&p=d
0 · Reply
NewsAndFilings
NewsAndFilings Oct. 25 at 2:28 PM
Weekly Rundown: $APRE Clinical Update $SNYR FOCUSfactor® Expansion $TOON $7.3 Million Financing $SIGL Major Encryption Milestone $SPTY Appoints Robert Fedder as CEO
0 · Reply
Bulltrader988
Bulltrader988 Oct. 24 at 2:36 PM
$APRE 👃👀 https://www.stocktitan.net/news/APRE/aprea-therapeutics-provides-clinical-update-from-acesot-1051-trial-zv04tgf74l20.html
0 · Reply
MsGrumpy
MsGrumpy Oct. 24 at 2:02 PM
$APRE Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051 https://www.globenewswire.com/news-release/2025/10/24/3172792/0/en/Aprea-Therapeutics-Provides-Clinical-Update-from-ACESOT-1051-Trial-Showing-Early-Signals-of-Activity-for-WEE1-Kinase-Inhibitor-APR-1051.html
0 · Reply
NewsAndFilings
NewsAndFilings Oct. 24 at 1:49 PM
$APRE Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051 https://www.globenewswire.com/news-release/2025/10/24/3172792/0/en/Aprea-Therapeutics-Provides-Clinical-Update-from-ACESOT-1051-Trial-Showing-Early-Signals-of-Activity-for-WEE1-Kinase-Inhibitor-APR-1051.html
0 · Reply
Giants67
Giants67 Oct. 24 at 1:17 PM
$APRE Aprea Therapeutics, provided an update on the ongoing Phase 1 ACESOT-1051 (A Multi-Center Evaluation of WEE1 Inhibitor in Patients with Advanced Solid Tumors, APR-1051) study. https://www.globenewswire.com/news-release/2025/10/24/3172792/0/en/Aprea-Therapeutics-Provides-Clinical-Update-from-ACESOT-1051-Trial-Showing-Early-Signals-of-Activity-for-WEE1-Kinase-Inhibitor-APR-1051.html
0 · Reply
Tigerfromasia
Tigerfromasia Oct. 23 at 10:11 PM
$APRE data is weak as fuck with 0 orr tbh but who gives a shit if we could get a pump
0 · Reply
Bulltrader988
Bulltrader988 Oct. 23 at 6:53 PM
$APRE tomorrow 👃👀
1 · Reply
Wakaas93
Wakaas93 Oct. 23 at 3:52 PM
$APRE Results tomorrow Target $3 https://x.com/pportfolioooo/status/1980337875326828605?s=46
0 · Reply
Bulltrader988
Bulltrader988 Oct. 22 at 7:43 PM
$APRE "...A poster titled Updated data from ABOYA-119: A phase 1/2a trial of ATRN-119, a novel macrocyclic ATR inhibitor, in patients with advanced solid tumors harboring DNA damage will be presented at the forthcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on Friday, October 24, 2025..." 👃👀 https://ir.aprea.com/news-releases/news-release-details/aprea-therapeutics-establishes-recommended-phase-2-dose-rp2d
0 · Reply
Latest News on APRE
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024

Jan 30, 2024, 8:00 AM EST - 1 year ago

Aprea Therapeutics to Present at DDR Inhibitors Summit 2024


Aprea Therapeutics to Present at BIO International Convention

May 30, 2023, 8:30 AM EDT - 2 years ago

Aprea Therapeutics to Present at BIO International Convention


Bulltrader988
Bulltrader988 Oct. 25 at 8:17 PM
$APRE 👃👀 https://finviz.com/quote.ashx?t=APRE&ty=c&ta=1&p=d
0 · Reply
NewsAndFilings
NewsAndFilings Oct. 25 at 2:28 PM
Weekly Rundown: $APRE Clinical Update $SNYR FOCUSfactor® Expansion $TOON $7.3 Million Financing $SIGL Major Encryption Milestone $SPTY Appoints Robert Fedder as CEO
0 · Reply
Bulltrader988
Bulltrader988 Oct. 24 at 2:36 PM
$APRE 👃👀 https://www.stocktitan.net/news/APRE/aprea-therapeutics-provides-clinical-update-from-acesot-1051-trial-zv04tgf74l20.html
0 · Reply
MsGrumpy
MsGrumpy Oct. 24 at 2:02 PM
$APRE Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051 https://www.globenewswire.com/news-release/2025/10/24/3172792/0/en/Aprea-Therapeutics-Provides-Clinical-Update-from-ACESOT-1051-Trial-Showing-Early-Signals-of-Activity-for-WEE1-Kinase-Inhibitor-APR-1051.html
0 · Reply
NewsAndFilings
NewsAndFilings Oct. 24 at 1:49 PM
$APRE Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051 https://www.globenewswire.com/news-release/2025/10/24/3172792/0/en/Aprea-Therapeutics-Provides-Clinical-Update-from-ACESOT-1051-Trial-Showing-Early-Signals-of-Activity-for-WEE1-Kinase-Inhibitor-APR-1051.html
0 · Reply
Giants67
Giants67 Oct. 24 at 1:17 PM
$APRE Aprea Therapeutics, provided an update on the ongoing Phase 1 ACESOT-1051 (A Multi-Center Evaluation of WEE1 Inhibitor in Patients with Advanced Solid Tumors, APR-1051) study. https://www.globenewswire.com/news-release/2025/10/24/3172792/0/en/Aprea-Therapeutics-Provides-Clinical-Update-from-ACESOT-1051-Trial-Showing-Early-Signals-of-Activity-for-WEE1-Kinase-Inhibitor-APR-1051.html
0 · Reply
Tigerfromasia
Tigerfromasia Oct. 23 at 10:11 PM
$APRE data is weak as fuck with 0 orr tbh but who gives a shit if we could get a pump
0 · Reply
Bulltrader988
Bulltrader988 Oct. 23 at 6:53 PM
$APRE tomorrow 👃👀
1 · Reply
Wakaas93
Wakaas93 Oct. 23 at 3:52 PM
$APRE Results tomorrow Target $3 https://x.com/pportfolioooo/status/1980337875326828605?s=46
0 · Reply
Bulltrader988
Bulltrader988 Oct. 22 at 7:43 PM
$APRE "...A poster titled Updated data from ABOYA-119: A phase 1/2a trial of ATRN-119, a novel macrocyclic ATR inhibitor, in patients with advanced solid tumors harboring DNA damage will be presented at the forthcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on Friday, October 24, 2025..." 👃👀 https://ir.aprea.com/news-releases/news-release-details/aprea-therapeutics-establishes-recommended-phase-2-dose-rp2d
0 · Reply
Carlosjr1996
Carlosjr1996 Oct. 21 at 9:51 AM
$APRE squeez coming 👀??
0 · Reply
sally2884
sally2884 Oct. 20 at 6:54 PM
$APRE "we may offer and sell shares of our common stock having an aggregate offering price of up to $3,000,000 Wainwright acting as our agent."
0 · Reply
NewsAndFilings
NewsAndFilings Oct. 19 at 5:16 AM
Weekly Rundown: $SIGL Cybersecurity Advances $MYSE Israeli Patent & US Patent Notice $PRSO Toronto Microcap Attendance & Purchase Orders $RDZN 6 Major Ecommerce Clients & Major Auto Insurance Win $APRE Establishes Recommended Phase 2 Dose
0 · Reply
IN0V8
IN0V8 Oct. 17 at 3:50 PM
$APRE announced the recommended Phase 2 dose of 1,100 mg once daily for ATRN-119 in its ongoing ABOYA-119 study for advanced solid tumors. The company is pausing further monotherapy enrollment to focus on combination therapies, leveraging ATRN-119’s potential synergistic effects with DNA-damaging agents. This strategic shift aims to enhance the therapeutic potential of ATRN-119, with ongoing discussions for combination studies in HPV+ head and neck cancer and other indications. The most recent analyst rating on (APRE) stock is a Buy with a $10.00 price target. https://www.msn.com/en-us/health/other/aprea-therapeutics-shifts-focus-to-combination-therapies/ar-AA1Ox205
0 · Reply
NewsAndFilings
NewsAndFilings Oct. 16 at 12:04 PM
Yesterday's Recap: $GNIS Strategic Letter of Intent With Metrospaces, Inc $APRE Establishes Recommended Phase 2 Dose $PRSO Presenting at Planet MicroCap Showcase: Toronto 2025
0 · Reply
MsGrumpy
MsGrumpy Oct. 15 at 12:58 PM
$APRE Aprea Therapeutics, Phase 2 Dosing Update: https://www.globenewswire.com/news-release/2025/10/15/3167027/0/en/Aprea-Therapeutics-Establishes-Recommended-Phase-2-Dose-RP2D-for-ATRN-119-Considering-Combination-Therapies.html
1 · Reply
NewsAndFilings
NewsAndFilings Oct. 15 at 12:57 PM
$APRE Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies https://www.globenewswire.com/news-release/2025/10/15/3167027/0/en/Aprea-Therapeutics-Establishes-Recommended-Phase-2-Dose-RP2D-for-ATRN-119-Considering-Combination-Therapies.html
0 · Reply
Giants67
Giants67 Oct. 15 at 12:41 PM
$APRE Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies https://www.globenewswire.com/news-release/2025/10/15/3167027/0/en/Aprea-Therapeutics-Establishes-Recommended-Phase-2-Dose-RP2D-for-ATRN-119-Considering-Combination-Therapies.html
0 · Reply
twighttrades1
twighttrades1 Oct. 15 at 1:11 AM
$APRE - id love to hear more concrete press woth a little more bang - but their being so slight with data presentations and and all is actually a good sign… wont take much for this to pop big
0 · Reply
thedonutman
thedonutman Oct. 3 at 3:48 PM
$APRE I am new here. Bought in yesterday. One question: are they expecting revenue sometime in the near future? Thank you.
1 · Reply
bgurps
bgurps Oct. 3 at 3:16 PM
0 · Reply
AlwaysLearning72
AlwaysLearning72 Oct. 3 at 12:36 PM
$APRE hopefully we get some positive news on their pipeline soon
0 · Reply